A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Inclusion Criteria:

- Subject has provided informed consent prior to any study-specific
activities/procedures

- Ambulatory postmenopausal women.

- Age 55 years or older

- Screening BMD value equivalent to a T-score less than or equal to -2.5 at the lumbar
spine, total hip, or femoral neck.

Exclusion Criteria:

- Administration of osteoporosis treatments or bone active treatments within specific
timeframes

- Vitamin D deficiency

- Diseases and conditions that affect bone metabolism (e.g., hypo/hyper-parathyroidism;
hypo/hyperthyroidism, unless stable and well-controlled)

- Contraindications to denosumab therapy (e.g., hypocalcemia)